SANGUINE
Unknown
3,000 enrolled
FATIGUE
Unknown
40 enrolled
TEDROMM
Unknown
200 enrolled
Step down ward
Unknown
344 enrolled
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
Unknown
80 enrolled
Amyloidosis Incidence in High-Risk Cardiac Device Patients
Unknown
100 enrolled
Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse
Unknown
20 enrolled
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Unknown
30 enrolled
CAREMM-2305
Unknown
1,600 enrolled
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)
Unknown
30 enrolled
CARS
Unknown
5,000 enrolled
PAMM-HAD1
Unknown
300 enrolled
CHIME
Unknown
10 enrolled
THD-MM-Reg
Unknown
1,000 enrolled
AATF/Che-1
Unknown
150 enrolled
Changing Over Time of Ascorbic Acid After Chemotherapy
Unknown
150 enrolled
The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
Unknown
30 enrolled
The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics
Unknown
500 enrolled
Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma
Unknown
398 enrolled
Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma
Unknown
30 enrolled
ctDNA Methylation Sequencing for Myeloma
Unknown
66 enrolled
COVID19-hematological Malignancies: the Italian Hematology Alliance
Unknown
250 enrolled
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
Unknown
100 enrolled
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
Unknown
67 enrolled
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Unknown
300 enrolled
Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance Imaging
Unknown
144 enrolled
Serum NGAL IN Patients With Multiple Myeloma
Unknown
60 enrolled
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Unknown
60 enrolled
SPACE2
Unknown
150 enrolled
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
Unknown
350 enrolled
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
Unknown
500 enrolled
MMSPORADGEN
Unknown
1,000 enrolled
BPMM
Unknown
35 enrolled
THERMAL
Unknown
20 enrolled
COSMOS
Unknown
500 enrolled
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19
Unknown
630 enrolled
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
Unknown
1,500 enrolled
ROADMAP-MM
Unknown
800 enrolled
Cardiovascular Complications of Carfilzomib Treatment
Unknown
46 enrolled
CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19)
Unknown
70 enrolled
Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)
Unknown
100 enrolled
DB-FU-IFM2009
Unknown
675 enrolled
ICARE
Unknown
60 enrolled
Multiple Myeloma (MM) Quality of Life (QOL) Study
Unknown
360 enrolled
CTFEA Myeloma Study
Unknown
200 enrolled
MYELODOM
Unknown
600 enrolled
Etiology of Multiple Myeloma: A Case-Control Study
Unknown
140 enrolled
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
Unknown
124 enrolled
EUCADD
Unknown
100 enrolled
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
Unknown
500 enrolled